The white paper "Optimizing the Cell and Gene Therapy Patient Journey Through Integrated CRO/CDMO Partnership" discusses the growing impact of cell and gene therapies (CGTs) in medicine, with a market expected to grow to $82.24 billion by 2032. It highlights the complex clinical trial process for these therapies, which can be improved through integrated partnerships between Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs). These partnerships streamline operations, enhance patient experience, and address challenges like supply chain complexity, manufacturing delays, and regulatory compliance. The paper also emphasizes the importance of patient-centric trial design, education, and support to improve access and outcomes.

Join for free to read